MARY CHERAMIE: Open Payments
NPI 1528563665 · THIBODAUX, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$692 in 20 payments from 8 companies in 2025. Trend: 2023 $354 · 2024 $550 · 2025 $692
Food & beverage: $692
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $342 |
| Dexcom, Inc. | 1 | $165 |
| Optinose US, Inc. | 3 | $53 |
| ABBVIE INC. | 2 | $39 |
| Smith+Nephew, Inc. | 1 | $29 |
| GENZYME CORPORATION | 1 | $23 |
| Organogenesis Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $20 |
Products named: NUCALA, DEXCOM G7 GSS (161), Xhance, QULIPTA, GRAFIX PL, DUPIXENT, VIA MATRIX, Ryaltris.
Industry payments across LA — which companies pay providers there.
